ViaDerma Donates 10,000 Units of VitaStem® to Ukraine

LAS VEGAS, Nev. — In the hospitals closest to the front lines, Ukrainian doctors and soldiers are facing a wound care crisis that doesn't make headlines — but demands an answer.

ViaDerma, Inc. (OTC: VDRM), a U.S.-based pharmaceutical technology company, has donated 10,000 units of VitaStem® — its FDA-registered OTC topical antibiotic — to Ukrainian hospitals and medical facilities. was delivered in partnership with Brother for Brother Until Victory, a Latvian NGO supporting frontline medical care in Ukraine. In two shipments, 10,000 units crossed the EU border. 

Built for exactly this

VitaStem® is the world's first product built on the SkinPass™ transdermal drug delivery platform — a patented technology that enables the antibiotic compounds to penetrate significantly deeper into wound tissue than conventional topicals. The technology allows wounds to heal much faster 

Each unit was repacked in blue and yellow packaging — Ukraine's national colours — and accompanied by an instructional video, enabling soldiers to administer the treatment themselves as a first-aid measure, without requiring a doctor to be present.

It was delivered primarily to frontline hospitals, where injured Ukrainian soldiers receive immediate medical help.

Says Peteris Bukovskis, Director of AB Wahrung, VitaStem®'s European distributor and the operational lead for the supply effort.

It also provides a critical solution for soldiers wounded in combat areas who cannot immediately access medical personnel. The recipients expressed deep gratitude — recognising VitaStem® as a unique and highly practical medical solution under wartime conditions.

The mission behind the mission.

The partnership was initiated by Andrew Otiko, Chief Market Acquisition Officer at ViaDerma, who leveraged existing contacts in Ukraine to build relationships with NGOs and coordinate delivery logistics.

For Dr. Christopher Otiko, ViaDerma's founder and CEO, a podiatric surgeon who spent three decades treating severe wounds, trying to prevent the loss of limbs in his patients. As a pharmaceutical company founded on the principle of improving global health outcomes, we recognise our responsibility to act during humanitarian crises.

We want victims of the war, such as soldiers,
to have the care we know VitaStem can provide.

A pattern of mission-led giving

Ukraine is not the first country to receive VitaStem® through ViaDerma's humanitarian programme. The company has previously donated its products to Uganda, Nigeria, Kenya, India, and the Philippines — a pattern that reflects not a PR strategy, but a founding conviction: that advanced pharmaceutical care should not be determined by geography or income.

About ViaDerma, Inc. ViaDerma, Inc. (OTC: VDRM) is a U.S.-based pharmaceutical technology company headquartered in Las Vegas, Nevada. The company's proprietary SkinPass™ transdermal drug delivery platform — protected by U.S. Patent No. 12,465,567, awarded November 2025 — enables active compounds to achieve significantly higher tissue concentrations than conventional topical delivery. Its flagship product, VitaStem®, is an FDA-registered OTC topical antibiotic. Founded by Dr. Christopher Otiko, DPM, MS — podiatric surgeon, researcher, and inventor — ViaDerma is developing applications of the SkinPass™ platform across multiple therapeutic categories.